
HELP Stock Forecast & Price Target
HELP Analyst Ratings
Bulls say
Helus Pharma is viewed positively because HLP003 has completed enrollment in the Phase 3 APPROACH adjunctive MDD study, with topline data due around mid-Nov and a prior Phase 2 result showing a ~13-point placebo-adjusted MADRS improvement, supporting meaningful de-risking of the lead program. Its outlook is also strengthened by HLP004, which posted about a 10-point HAM-A reduction in GAD and could open a second large market, while 2Q26 R&D of $28.9MM, G&A of $13.7MM, and $157.3MM in cash, plus a $50MM financing, suggest adequate funding into the next readout. Additional support comes from a seasoned neuropsychiatry CEO, improving regulatory and M&A sentiment, and external validation of psychedelic mechanisms that enhances confidence in both pipeline and strategic value.
Bears say
Helus Pharma is viewed negatively because its value proposition remains highly speculative, with HLP003 and HLP004 still in clinical development and subject to meaningful execution, regulatory, and commercialization risk. Although cash increased to $157.3 million as of March 31 and a $50 million raise closed on June 25, 2026, the model still assumes annual equity raises of $150 million in FY2027E-FY2029E, highlighting likely dilution and continued dependence on capital markets. The outlook is further pressured by delayed launch timing for HLP003 to F2029E and HLP004 to F2030E, alongside reduced asset valuations to $52/share and $18/share and a lower total firm value of about $5.6 billion.
This aggregate rating is based on analysts' research of Helus Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.
HELP Analyst Forecast & Price Prediction
Start investing in HELP
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Helus Pharma Inc (HELP) Forecast
HELP Analyst Forecast & Price Prediction
Start investing in HELP
Order type
Buy in
Order amount
Est. shares
0 shares